UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
TO
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
REGULUS
THERAPEUTICS INC.
(Name of Subject Company (Issuer))
REDWOOD
MERGER SUB INC.
(Offeror)
A Wholly Owned Subsidiary of
NOVARTIS AG
(Parent
of Offeror)
(Names of Filing Persons (identifying status as offeror, issuer or other person))
Common Stock, par value $0.001 per share
(Title of Class of Securities)
75915K309
(CUSIP Number of Class of Securities)
Karen L. Hale
Chief Legal and Compliance Officer
Novartis AG
Lichstrasse 35
CH-4056 Basel
Switzerland
Telephone: +41-61-324-1111
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications on Behalf of Filing Persons)
Copies
to:
Catherine J. Dargan, Esq.
Michael J. Riella, Esq.
Kerry S. Burke, Esq.
Covington & Burling LLP
One CityCenter
850 Tenth Street, NW
Washington, DC 20001-4956
+1 (202) 662-6000
¨ Check
the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. Check the appropriate
boxes below to designate any transactions to which the statement relates:
x Third-party
offer subject to Rule 14d-1.
¨ Issuer
tender offer subject to Rule 13e-4.
¨ Going-private
transaction subject to Rule 13e-3.
¨ Amendment
to Schedule 13D under Rule 13d-2.
Check
the following box if the filing is a final amendment reporting the results of the tender offer: x
If applicable, check the appropriate box(es) below to designate the
appropriate rule provision(s) relied upon:
¨ Rule 13e-4(i) (Cross-Border
Issuer Tender Offer)
¨ Rule 14d-1(d) (Cross-Border
Third Party Tender Offer)
This
Amendment No. 3 to the Tender Offer Statement on Schedule TO (this “Amendment”) amends and supplements
the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on May 27, 2025 (as it may be amended
and supplemented from time to time, the “Schedule TO”) by (i) Redwood Merger Sub Inc., a Delaware corporation
(“Purchaser”) and an indirect wholly owned subsidiary of Novartis AG, a company limited by shares (Aktiengesellschafl)
incorporated under the laws of Switzerland (“Parent”) and (ii) Parent. The Schedule TO relates to the offer (the
“Offer”) to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”),
of Regulus Therapeutics Inc., a Delaware corporation (the “Company”), in exchange for (a) $7.00 in cash per Share,
subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a “CVR”)
per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without
interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth
in, the CVR Agreement to be entered into between Parent and a rights agent as of or prior to the date and time of the irrevocable acceptance
for payment by Purchaser of the Shares that have been validly tendered and not validly withdrawn pursuant to and subject to the conditions
of the Offer. The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated May 27,
2025, and in the related Letter of Transmittal, copies of which are attached as Exhibits (a)(1)(A) and (a)(1)(B) to the Schedule
TO, respectively.
This Amendment is being filed solely to amend
and supplement items to the extent specifically provided herein. Except as otherwise set forth in this Amendment, the information set
forth in the Schedule TO, including all exhibits thereto, remains unchanged and is incorporated herein by reference to the extent relevant
to the items in this Amendment. This Amendment should be read together with the Schedule TO. Capitalized terms used but not defined herein
have the meanings ascribed to them in the Schedule TO, as amended by this Amendment.
Items 1 through 9 and Item 11.
Items 1 through 9 and Item 11 of the Schedule TO are hereby amended
and supplemented as follows:
“The Offer expired at one minute
past 11:59 p.m., New York City time, on June 24, 2025 (such date and time, the “Offer Expiration Time”), and the
Offer was not extended. The Depositary has advised that, as of the Offer Expiration Time, a total of 56,374,397 Shares (excluding Shares
with respect to which Notices of Guaranteed Delivery were delivered but were not yet “received” (as such term is defined in
Section 251(h) of the DGCL)) were validly tendered pursuant to the Offer and not validly withdrawn, representing approximately
74.49% of the Shares outstanding as of immediately prior to the Offer Expiration Time. In addition, the Depositary has advised that,
as of the Offer Expiration Time, Notices of Guaranteed Delivery had been delivered with respect to 5,584,804 additional Shares, representing
approximately 7.38% of the outstanding Shares as of immediately prior to the Offer Expiration Time.
As of the Offer Expiration Time, the
number of Shares validly tendered pursuant to the Offer and not validly withdrawn satisfied the Minimum Condition, and all other conditions
to the Offer had been satisfied. Promptly following the Offer Expiration Time, Purchaser irrevocably accepted for payment all Shares validly
tendered pursuant to the Offer and not validly withdrawn.
Following acceptance for payment of
the Shares, on June 25, 2025, Purchaser effected the Merger in accordance with Section 251(h) of the DGCL, without a meeting
of the Company’s stockholders and without a vote or any further action by the Company’s stockholders.
The Shares were delisted and ceased
to trade on Nasdaq prior to the opening of business on June 25, 2025. Parent and Purchaser intend to take steps to cause the termination
of the registration of the Shares under the Exchange Act and the suspension of all of the Company’s reporting obligations under
the Exchange Act as promptly as practicable.
On June 25, 2025, Parent issued
press releases announcing the expiration and results of the Offer and the consummation of the Merger. The full text of the press releases
are attached as Exhibits (a)(5)(F) and (a)(5)(G) hereto, and incorporated herein by reference.”
Item 12. Exhibits.
Item 12 of the Schedule TO is hereby amended and supplemented by adding
the following exhibit:
| Exhibit No. |
Description |
| |
|
| (a)(5)(F) |
Press Release issued by Novartis AG, dated June 25, 2025. |
| |
|
| (a)(5)(G) |
Press Release issued by Novartis AG, dated June 25, 2025. |
SIGNATURES
After due inquiry and to the
best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true,
complete and correct.
Redwood Merger Sub Inc.
| |
/s/ Jaime Huertas |
| |
Name: |
Jaime Huertas |
| |
Title: |
Secretary |
Novartis AG
| |
/s/ Jonathan Emery |
| |
Name: |
Jonathan Emery |
| |
Title: |
As Attorney |
| |
/s/ Tariq El Rafie |
| |
Name: |
Tariq El Rafie |
| |
Title: |
As Attorney |
Date: June 25, 2025
